Tonix Pharmaceuticals is currently enrolling participants in a Phase 3 trial for military-related posttraumatic stress disorder.  For more information, please visit or (NCT03062540).

News / Press Releases
: News / Press Releases

News / Press Releases

Latest News

Tonix Pharmaceuticals to Present FDA Breakthrough Therapy-Designated PTSD Program at the MicroCap Conference in New York

Read Press Release

Upcoming Event

2018 Annual Meeting of the Shareholders

Offices of Lowenstein Sandler LLP - 1251 Avenue of the Americas, New York, New York 10020